Advice

in the absence of a submission from the holder of the marketing authorisation:

cabozantinib (Cabometyx) is not recommended for use within NHSScotland.

Indication under review: As monotherapy for the treatment of hepatocellular carcinoma in adults who have previously been treated with sorafenib.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.

Download detailed advice355KB (PDF)

Download

Medicine details

Medicine name:
cabozantinib (Cabometyx)
SMC ID:
SMC2160
Indication:
As monotherapy for the treatment of hepatocellular carcinoma in adults who have previously been treated with sorafenib.
Pharmaceutical company
Ipsen Ltd
BNF chapter
Submission type
Non submission
Status
Not recommended
Date advice published:
11 February 2019